138 results
8-K
EX-99.1
ME
23andMe Holding Co - Ordinary Shares
18 Apr 24
23andMe announces CEO’s intention to pursue a potential take-private
8:07am
Committee on March 28, 2024, comprised of independent directors, to review strategic alternatives that may be available to 23andMe to maximize shareholder
S-8
EX-23.1
ME
23andMe Holding Co - Ordinary Shares
22 Mar 24
Registration of securities for employees
5:02pm
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated May 25, 2023, with respect
8-K
EX-99.2
ME
23andMe Holding Co - Ordinary Shares
8 Jan 24
Regulation FD Disclosure
7:45am
in iPSC-derived neuron models epithelial biology: screen mucociliary function in ALI culture mast cell biology: screen in IgE dependent & independent
S-8
ME
23andMe Holding Co - Ordinary Shares
15 Sep 23
Registration of securities for employees
4:06pm
, even though less than a quorum, or (3) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion … on December 9, 2022).
Opinion of Morgan, Lewis & Bockius LLP.
Consent of KPMG LLP, independent registered public accounting firm.
Consent of Morgan, Lewis
S-8
EX-23.1
ME
23andMe Holding Co - Ordinary Shares
15 Sep 23
Registration of securities for employees
4:06pm
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated May 25, 2023, with respect
S-8
EX-99.1
0jonb9j3wzm5kiz
15 Sep 23
Registration of securities for employees
4:06pm
8-K
9fn006k4j0
11 Sep 23
Departure of Directors or Certain Officers
4:06pm
8-K
EX-99.1
hxd 4jtco4lrmo7o
1 Sep 23
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
12:00am
DEFR14A
5w4bfj8ek0i he4f
4 Aug 23
Revised proxy
4:05pm
DEFR14A
jwe23 dmb39o
26 Jul 23
Revised proxy
9:14pm
DEFA14A
0pje 25z9
26 Jul 23
Additional proxy soliciting materials
4:05pm
8-K
EX-99.1
x54kaxr2yn8 cc3qdmm
17 Apr 23
Regulation FD Disclosure
4:10pm
8-K
EX-3.1
4rvl46121ti 6xzr
9 Dec 22
Departure of Directors or Certain Officers
8:05am
8-K
EX-10.1
sy3npepl8cfxtxbi
9 Dec 22
Departure of Directors or Certain Officers
8:05am
8-K
EX-99.1
4pgu ahrh3be9o
9 Nov 22
Investor Presentation November 2022
7:30am
424B3
12hxr0 u9d7l
7 Nov 22
Prospectus supplement
4:33pm